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The starting point for this anthology is what Michael Santoro calls the “unravel-
ling of the grand bargain” between the pharmaceutical industry and society. 
During the most part of the history of the pharmaceutical industry, the com-
mercial success of pharmaceutical companies seems to have gone hand-in-hand 
with enormously increased access in society to many kinds of innovative life-
saving and life-enhancing drugs. But as the twenty-first century begins, public 
distrust and resentment of the industry is at an all-time high. Reports and com-
plaints flourish about ever-rising drug prices; blatantly misleading advertisement 
campaigns; the industry’s aggressive stance in trade negotiations with third world 
countries; and even bribery of physicians to prescribe particular drugs, and of 
scientists to only publish trials with positive results. All in all, the received opin-
ion seems to be that pharmaceutical companies care infinitely more about profits 
than about people.
So how can the public’s trust in the pharmaceutical industry be restored? 
What kind of ethical requirements should be imposed on pharmaceutical com-
panies, or in what way could the regulatory landscape surrounding pharmaceu-
ticals be changed to avoid these kinds of problems? These are the kinds of 
questions addressed in the present collection. With impressive ambition, Santoro 
and Gorrie have gathered as many as 24 papers on a wide array of interesting 
topics. The collection is divided into four main parts: In part I, ethical issues 
related to the research activities of pharmaceuticals are discussed; the conflict 
between scientific, ethical and economic goals in clinical research, and the rights 
of people participating in clinical trials. In part II, emphasis is on ethical and 
political issues related to the marketing activities of pharmaceuticals; the regula-
tion of direct-to-consumer advertising and fairness in allocation of pharmaceuti-
cal benefits. Part III covers the heated debate over patents and intellectual property 
rights from both philosophical, political and historical perspectives. Finally, 
part IV contains some reflections on and suggestions for the future of the phar-
maceutical industry.
It is hard not to be impressed by the great diversity of authors that Santoro 
and Gorrie have managed to gather in their book. Participating authors have 
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extremely diverse backgrounds: they are economists, lawyers, philosophers and 
medical scholars, as well as practicing physicians, politicians, officers of regula-
tory bodies, and activists. I guess that my main criticism of the collection is that, 
for obvious reasons, this diversity in authorship makes the whole somewhat 
eclectic: While some papers are the result of years of academic research, for 
instance, others are more of personal reflections. While some papers are quite 
easily accessible, furthermore, others are rather technical or require considerable 
background knowledge, and while some papers are very innovative, others bring 
little new to the table. But like with most collections of papers, there is probably 
little point in reading this book from cover to cover. The great diversity of the 
collection could certainly be seen as a good thing as well; it means that it is quite 
likely to be useful in many kinds of both academic and non-academic contexts, 
and I am sure that almost everyone can find at least something they like in this 
collection.
I was personally most intrigued by Santoro’s elaborate philosophical introduc-
tions, both to the collection as a whole and to its four main parts. Writing intro-
ductions to collections of other people’s papers can be difficult, and must have 
been especially difficult given the eclectic nature of this particular collection. 
With notable acumen, however, Santoro’s introductions give a both philosophi-
cally and empirically insightful overview of the many interesting ethical and 
political issues which the practices of the pharmaceutical industry give rise to — 
and these introductions often go well beyond the contents of the papers which 
succeed them. At the core of most ethical and political debates in this area, San-
toro suggests, lies the issue of profit versus people, or the conflict between the 
profit-maximising nature of companies and the medical needs of the public. The 
challenge is to find a reasonable balance between these two, and this challenge 
permeates issues like what the research activities of pharmaceuticals should be, 
fairness in allocation of pharmaceutical benefits, and what an ethically legitimate 
patent regime could look like. Although it seems difficult to determine this bal-
ance a priori, Santoro suggests (with many other authors in the collection), it 
may be possible to reach more of a consensus through increased collaboration 
between the many stakeholders of the global healthcare system. I will return to 
this suggestion below.
Besides Santoro’s introductions, I suggest that readers interested in moral and 
political philosophy may find three brilliant contributions to the debate over 
patents included in this collection especially worth their consideration. In chap-
ter 15, Patricia Werhane and Michael Gorman critically examine some popular 
philosophical justifications for intellectual property rights, especially the stan-
dard rights-based defence of such property. While the idea that invention or 
development of something normally should confer a set of special entitlements 
to this thing may be plausible as such, they argue, this idea actually sits uneasily 
with the current patent regime related to the pharmaceutical industry. Intellec-
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tual inventions, like the development of a new drug, are not the result of isolated 
scientists or companies but rather of a whole network of people, technology 
and ideas — thus, it would make more sense of crediting society as a whole for a 
certain invention than giving exclusive patent rights to individual companies. 
Werhane and Gorman propose what they call an alliance model, or a network 
approach, which they suggest could replace the current individualised patent 
regime.
In chapter 22, Nien-hê Hsieh argues that even if giving strong and exclusive 
patent rights to individual pharmaceutical companies could be justified on a 
political level, which on one interpretation is what proponents of the pharma-
ceutical industry typically suggest, these companies themselves may have ethical 
obligations to refrain from protecting these rights, and to for example provide 
cheaper drugs to the victims of the African HIV/AIDS crisis. Just because you 
have a right to do something, namely, this doesn’t necessarily translate into it 
being right to do so. Hsieh’s argument is a fascinating one and I find myself in 
agreement with most of what he says. In chapter 19, finally, James Thuo Gathii 
critically examines the latest in a row of excuses for not responding to the Afri-
can HIV/AIDS crisis given by American pharmaceutical companies — the idea 
that the real problem is not poor people’s lack of access to pharmaceuticals as 
such, but simply the fact that they are poor. Gathii argues that many poor peo-
ple certainly could be saved if these companies were to refrain from protecting 
their patent rights and, indeed, there are some indications that the current pat-
ent regime actually has contributed to the impoverished state of the sub-Saharan 
region.
Readers more interested in global health law in general may find a number of 
further papers worthwhile. Chapter 2 introduces the development of interna-
tional norms for the use of human subjects in clinical research, and chapters 3 
and 4 elaborate on relevant regulations specifically developed for trials involving 
children. In chapter 7, the Congressman Rush Holt gives his insightful take on 
the debate over stem-cell research in the US and its regulatory results. Thomas 
Abrams gives a very accessible and interesting account of the development of 
direct-to-consumer advertising and how legislators have sought to control it in 
chapter 9. Moreover, Scott Danzis guides the reader through the extremely com-
plex legislative landscape surrounding “off-label” drug promotion in chapter 11.
I obviously cannot account for all the papers in the collection in this context, 
but let me just mention a few more which I believe stand out. I was quite taken 
aback by Valentine Burroughs’ (chapter 5) account of how patients from racial 
and ethnic minorities actually are doubly discriminated against by the practices 
of the pharmaceutical industry and the US healthcare system. Not only are 
healthcare practitioners often poorly educated to cater for the particular needs of 
minorities, but the standard focus on non-minority subjects in the research activ-
ities of the pharmaceutical industry actually makes it much more difficult for 
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healthcare practitioners to cater to these needs. Of course, as Charles Bardes 
makes quite clear in chapter 8, this is just a small part of the enormous ethical 
complexities involved in the healthcare practitioner’s day-to-day job of prescrib-
ing medication. With great insight, Bardes introduces some further difficult 
dilemmas involved in giving advice on pharmaceuticals, illustrating quite nicely 
how the ethical difficulties facing modern clinicians are difficult to capture in 
abstract philosophical schemas. In chapter 17, finally, Martin Delaney gives an 
insightful account of what it is like to be on the other side of these choices, and 
how patient advocacy groups can help to make the healthcare system better 
adapted to actual healthcare needs. Relating his experiences from the American 
HIV/AIDS patient movement, Delaney gives some interesting suggestions as to 
how patient advocacy groups can increase their credibility by abiding by a set of 
ethical guidelines.
So how can we chart a sustainable path for the pharmaceutical industry in the 
twenty-first century? This is the topic of the last part of the collection and a cen-
tral theme, not just in the papers in this part but throughout the book, seems to 
be that increased collaboration by the many stakeholders of the global healthcare 
system is needed. Many authors suggest that actors from both the public and 
the private sector need to work together to find solutions; alliances need to be 
formed between pharmaceutical companies, governments, non-governmental 
organisations, and patients. I am perhaps not entirely convinced by this kind of 
suggestions — while talk of alliances certainly may look good on paper, and 
some inspiring precedents of successful collaborations in the area exist, it just 
seems hard to believe that the pharmaceutical industry voluntarily would open 
itself up to outside influence in this way in a larger scale. But perhaps we will 
just have to hope that they do. As far as the authors of this collection are con-
cerned, in any case, the only alternative is renationalisation, or governmental 
regulation of every last detail of the industry’s activities, and this isn’t held out as 
a particularly attractive alternative.
I sincerely recommend this anthology to everyone interested in global health 
law or health politics, as well as to everyone with interests in healthcare ethics or 
business ethics more generally. The ethical and political issues raised by the prac-
tices of the pharmaceutical industry are both intriguing and extremely important 
to consider, and this anthology highlights many of them. Whether the pharma-
ceutical industry will be able to overcome the many ethical problems currently 
associated with it remains to be seen, and this anthology can perhaps not present 
the final solution. Hopefully, however, it can be a first step in a more promising 
direction.
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